I’d buy these 2 FTSE 100 dividend stocks to retire on a passive income

Roland Head explains how he plans to use FTSE 100 dividend stocks to provide a reliable retirement income. These two shares both yield over 5.5%.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

When I retire, I plan to use my portfolio of dividend shares to provide a passive income. Today, I’m going to look at two FTSE 100 dividend stocks I think have the long-term quality needed to help fund my retirement.

A global growth trend

Most developed countries around the world are reporting ageing populations. More people are living longer, while birth rates are falling. At the same time, economic development in emerging markets is driving demand for improved healthcare and consumer goods.

These trends suggest to me that demand for modern healthcare is likely to increase for the foreseeable future. This is one reason why I’ve chosen FTSE 100 pharmaceutical group GlaxoSmithKline (LSE: GSK) for my first pick.

GSK missed out on the rally enjoyed by many pharma stocks last year. This was partly because sales of regular vaccines business suffered during lockdown, as people stayed away from doctors’ surgeries.

However, the group’s turnaround is making progress. Sales of new pharmaceuticals rose by 12% to £2.5bn during the third quarter, accounting for 30% of all revenue. Glaxo also remained very profitable, with an operating margin of 22%.

I expect this progress to continue. I’m also positive on the outlook for the consumer healthcare business, which owns brands such as Sensodyne and Nicorette. Boss Emma Walmsley plans to spin out this division into a new company over the next year or so. I think this will release value for shareholders.

Glaxo’s unloved status means this FTSE 100 dividend stock currently trades on just 12 times forecast earnings. The stock’s dividend hasn’t been cut for 15 years and now provides a yield of 5.7%. I think GSK shares look too cheap. I’d bid up the share price if the company’s 2020 results showed continued progress.

I already own a chunk of GSK stock, but I’m thinking about buying more.

Still growing after 185 years

Companies with long histories aren’t guaranteed to survive. But I believe a long, successful history is a good clue a business will continue to evolve and grow in the future. One long-lived company I rate very highly is pensions and insurance firm Legal & General Group (LSE: LGEN).

Legal & General wrote its first life assurance policy in 1836. In 2019, the company reported assets under management of £1,196bn and generated a pre-tax profit of £2.1bn. Shareholders received £1.1bn in dividends, all of which was covered by surplus cash.

In recent years, the firm’s strategy of buying out corporate pension schemes has supported continued growth. So-called Pension Risk Transfer sales totalled £11.4bn in 2019.  This has enabled Legal & General to increase the dividend regularly while maintaining good levels of earnings cover.

Looking ahead, chief executive Nigel Wilson says that dividend payments are expected to total £5.6bn-£5.9bn between 2020 and 2024. That’s equivalent to around 36% of the current share price — not bad, in my view.

Investor worries about low interest rates and the outlook for the global economy have kept Legal & General’s share price pinned down over the last year. This has left the stock valued on just nine times forecast earnings, with a dividend yield of 6.6%. I’d like to buy this FTSE 100 dividend stock for my portfolio.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »